These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11261337)

  • 1. [Current aspects of defibrillator therapy in congestive heart failure].
    Trappe HJ; Meine M; Pfitzner P; Voigt B; Weismüller P
    Z Kardiol; 2001; 90 Suppl 1():28-34. PubMed ID: 11261337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biventricular stimulation therapy in patients with heart failure and tachycardic arrhythmias. Indications--results--prospects].
    Trappe HJ
    Biomed Tech (Berl); 2002 Oct; 47(9-10):243-9. PubMed ID: 12369212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow up of patients with implantable cardioverter-defibrillators and mild, moderate, or severe impairment of left ventricular function.
    Trappe HJ; Wenzlaff P; Pfitzner P; Fieguth HG
    Heart; 1997 Sep; 78(3):243-9. PubMed ID: 9391285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [10 years of therapy with implantable defibrillators--observation in 353 patients].
    Trappe HJ; Wenzlaff P; Klein H; Pfitzner P; Fieguth HG; Kielblock B; Lichtlen PR
    Z Kardiol; 1995 Mar; 84(3):222-31. PubMed ID: 7732715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-chamber versus dual-chamber implantable cardioverter defibrillators: indications and clinical results.
    Trappe HJ; Achtelik M; Pfitzner P; Voigt B; Weismüller P
    Am J Cardiol; 1999 Mar; 83(5B):8D-16D. PubMed ID: 10089834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age dependent efficacy of implantable cardioverter-defibrillator treatment: observations in 450 patients over an 11 year period.
    Trappe HJ; Pfitzner P; Achtelik M; Fieguth HG
    Heart; 1997 Oct; 78(4):364-70. PubMed ID: 9404252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
    Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure.
    Biton Y; Rosero S; Moss A; Zareba W; Kutyifa V; Baman J; Barsheshet A; McNitt S; Polonsky B; Goldenberg I
    Am J Cardiol; 2018 Mar; 121(5):615-620. PubMed ID: 29307459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'modern' implantable cardioverter-defibrillator: comparing it to those of the late 1980s.
    Trappe HJ
    Am J Cardiol; 1996 Sep; 78(5A):3-8. PubMed ID: 8820829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
    Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R
    ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification.
    Providência R; Boveda S; Defaye P; Segal O; Algalarrondo V; Sadoul N; Lambiase P; Piot O; Klug D; Perier MC; Bouzeman A; Barra S; Bories MC; Gras D; Fauchier L; Bordachar P; Babuty D; Deharo JC; Leclercq C; Marijon E;
    Am J Cardiol; 2016 Oct; 118(8):1225-1232. PubMed ID: 27561197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
    Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
    N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction.
    van der Lingen ACJ; Timmer SAJ; Allaart LJH; Rijnierse MT; van de Ven PM; van Rossum AC; Kemme MJB; van Halm VP; Allaart CP
    Am J Cardiol; 2019 Aug; 124(4):560-566. PubMed ID: 31270031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.